- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.02. | NHS "isn't delivering equitable care for rare diseases" | ||
| 27.02. | Moderna closes on EU approval for combined flu/COVID jab | ||
| 27.02. | Boehringer gets FDA's second 'national priority' approval | ||
| 27.02. | US lawmakers take FDA to task over rare diseases record | ||
| 27.02. | Generate's IPO gets over the line, raising $400m | ||
| 26.02. | Eisai unveils digital platform for kidney cancer patients | ||
| 26.02. | Boehringer bets up to $500m on Sitryx immunology programme | ||
| 26.02. | Lilly says orforglipron tops Wegovy pill in diabetes trial | ||
| 26.02. | Asahi Kasei buys antiviral firm Aicuris for €780m | ||
| 26.02. | Changes at the top of Sarepta, Alkermes, as CEOs depart | ||
| 25.02. | Novo Nordisk beefs up in oral obesity drugs with Vivtex deal | ||
| 25.02. | GSK grows pipeline with 35Pharma takeover, Frontier deal | ||
| 25.02. | Novo Nordisk to cut GLP-1 prices in tough US market | ||
| 25.02. | Astellas bets on Vir cancer drug, and other licensing deals | ||
| 25.02. | In brief SOTU remarks, Trump asks Congress to "codify" MFN | ||
| 24.02. | UK spurs prescribing of obesity jab Mounjaro with GP bonus | ||
| 24.02. | After CagriSema blow, Novo reveals data for obesity 'triple' | ||
| 24.02. | Joy as NICE changes tack on first NHS vitiligo treatment | ||
| 24.02. | MSD splits pharma business, hiving off oncology | ||
| 24.02. | FDA maps new regulatory route for ultra-rare diseases | ||
| 23.02. | FDA clears first all-oral combo for first-line CLL treatment | ||
| 23.02. | Gilead buys cell therapy partner Arcellx for up to $7.8bn | ||
| 23.02. | Head-to-head trial dents Novo Nordisk's obesity hopes | ||
| 23.02. | Patients struggling with NHS complexity, says report | ||
| 23.02. | What next for pharma as SCOTUS strikes down Trump tariffs? |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.